These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 27390068)

  • 1. Design and synthesis of 1H-pyrazolo[3,4-c]pyridine derivatives as a novel structural class of potent GPR119 agonists.
    Matsuda D; Kobashi Y; Mikami A; Kawamura M; Shiozawa F; Kawabe K; Hamada M; Oda K; Nishimoto S; Kimura K; Miyoshi M; Takayama N; Kakinuma H; Ohtake N
    Bioorg Med Chem Lett; 2016 Aug; 26(15):3441-6. PubMed ID: 27390068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel 3H-[1,2,3]triazolo[4,5-c]pyridine derivatives as GPR119 agonists: Synthesis and structure-activity/solubility relationships.
    Matsuda D; Kobashi Y; Mikami A; Kawamura M; Shiozawa F; Kawabe K; Hamada M; Nishimoto S; Kimura K; Miyoshi M; Takayama N; Kakinuma H; Ohtake N
    Bioorg Med Chem; 2017 Aug; 25(16):4339-4354. PubMed ID: 28662959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and optimization of N-(3-(1,3-dioxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-4-yloxy)phenyl)benzenesulfonamides as novel GPR119 agonists.
    Yu M; Ken Zhang J; Wang Y; Zhu J; Kayser F; Medina JC; Siegler K; Conn M; Shan B; Grillo MP; Coward P; Jim Liu J
    Bioorg Med Chem Lett; 2014 Jan; 24(1):156-60. PubMed ID: 24332491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and structure-activity relationship of dihydrobenzofuran derivatives as novel human GPR119 agonists.
    Ye XY; Morales CL; Wang Y; Rossi KA; Malmstrom SE; Abousleiman M; Sereda L; Apedo A; Robl JA; Miller KJ; Krupinski J; Wacker DA
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2539-45. PubMed ID: 24755425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and biological evaluation of novel 7-azaspiro[3.5]nonane derivatives as GPR119 agonists.
    Matsuda D; Kawamura M; Kobashi Y; Shiozawa F; Suga Y; Fusegi K; Nishimoto S; Kimura K; Miyoshi M; Takayama N; Kakinuma H; Ohtake N
    Bioorg Med Chem; 2018 May; 26(8):1832-1847. PubMed ID: 29486951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and optimization of 5-fluoro-4,6-dialkoxypyrimidine GPR119 agonists.
    Buzard DJ; Kim SH; Lehmann J; Han S; Calderon I; Wong A; Kawasaki A; Narayanan S; Bhat R; Gharbaoui T; Lopez L; Yue D; Whelan K; Al-Shamma H; Unett DJ; Shu HH; Tung SF; Chang S; Chuang CF; Morgan M; Sadeque A; Chu ZL; Leonard JN; Jones RM
    Bioorg Med Chem Lett; 2014 Sep; 24(17):4332-5. PubMed ID: 25088191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and biological evaluation of aryl N-methoxyamide derivatives as GPR119 agonists.
    Jang YK; Lee KM; Jung KY; Kang SK; Pagire SH; Lee JM; Pagire HS; Kim KR; Bae MA; Lee H; Rhee SD; Ahn JH
    Bioorg Med Chem Lett; 2017 Aug; 27(16):3909-3914. PubMed ID: 28666737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and biological evaluation of a novel class of potent TGR5 agonists based on a 4-phenyl pyridine scaffold.
    Zhu J; Ning M; Guo C; Zhang L; Pan G; Leng Y; Shen J
    Eur J Med Chem; 2013 Nov; 69():55-68. PubMed ID: 24007860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and synthesis of novel pyrimido[5,4-d]pyrimidine derivatives as GPR119 agonist for treatment of type 2 diabetes.
    Fang Y; Xu J; Li Z; Yang Z; Xiong L; Jin Y; Wang Q; Xie S; Zhu W; Chang S
    Bioorg Med Chem; 2018 Aug; 26(14):4080-4087. PubMed ID: 30100020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and biological evaluation of 2-(4-(methylsulfonyl)phenyl)pyridine derivatives as GPR119 agonists.
    Zhou Y; Zhu X; Zhang L; Tang C; Feng B
    Chem Biol Drug Des; 2019 Jan; 93(1):67-74. PubMed ID: 30120879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus.
    Ha TY; Kim YS; Kim CH; Choi HS; Yang J; Park SH; Kim DH; Rhee JK
    Arch Pharm Res; 2014 May; 37(5):671-8. PubMed ID: 23897163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of novel and potent GPR119 agonists with a spirocyclic structure.
    Harada K; Mizukami J; Kadowaki S; Matsuda I; Watanabe T; Oe Y; Kodama Y; Aoki K; Suwa K; Fukuda S; Yata S; Inaba T
    Bioorg Med Chem Lett; 2018 Apr; 28(7):1228-1233. PubMed ID: 29519733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and structure-activity relationship of fused-pyrimidine derivatives as a series of novel GPR119 agonists.
    Negoro K; Yonetoku Y; Moritomo A; Hayakawa M; Iikubo K; Yoshida S; Takeuchi M; Ohta M
    Bioorg Med Chem; 2012 Nov; 20(21):6442-51. PubMed ID: 23010456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2,5-Disubstituted pyridines as potent GPR119 agonists.
    Wu Y; Kuntz JD; Carpenter AJ; Fang J; Sauls HR; Gomez DJ; Ammala C; Xu Y; Hart S; Tadepalli S
    Bioorg Med Chem Lett; 2010 Apr; 20(8):2577-81. PubMed ID: 20227877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and biological evaluation of 1H-pyrrolo[2,3-b]pyridine and 1H-pyrazolo[3,4-b]pyridine derivatives as c-Met inhibitors.
    Liu N; Wang Y; Huang G; Ji C; Fan W; Li H; Cheng Y; Tian H
    Bioorg Chem; 2016 Apr; 65():146-58. PubMed ID: 26950400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and structure-activity relationship of 4-amino-2-phenylpyrimidine derivatives as a series of novel GPR119 agonists.
    Negoro K; Yonetoku Y; Maruyama T; Yoshida S; Takeuchi M; Ohta M
    Bioorg Med Chem; 2012 Apr; 20(7):2369-75. PubMed ID: 22365911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of potent and selective GPR119 agonists for type II diabetes.
    Szewczyk JW; Acton J; Adams AD; Chicchi G; Freeman S; Howard AD; Huang Y; Li C; Meinke PT; Mosely R; Murphy E; Samuel R; Santini C; Yang M; Zhang Y; Zhao K; Wood HB
    Bioorg Med Chem Lett; 2011 May; 21(9):2665-9. PubMed ID: 21273063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based design, synthesis, and evaluation of 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine derivatives as novel c-Met inhibitors.
    Zhang L; Zhang B; Zhao J; Zhi Y; Wang L; Lu T; Chen Y
    Eur J Med Chem; 2017 Sep; 138():942-951. PubMed ID: 28755635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of small-molecule crystal structures to address solubility in a novel series of G protein coupled receptor 119 agonists: optimization of a lead and in vivo evaluation.
    Scott JS; Birch AM; Brocklehurst KJ; Broo A; Brown HS; Butlin RJ; Clarke DS; Davidsson O; Ertan A; Goldberg K; Groombridge SD; Hudson JA; Laber D; Leach AG; Macfaul PA; McKerrecher D; Pickup A; Schofield P; Svensson PH; Sörme P; Teague J
    J Med Chem; 2012 Jun; 55(11):5361-79. PubMed ID: 22545772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of pyrazolo[3,4-d]pyrimidine derivatives as GPR119 agonists.
    Gillespie P; Goodnow RA; Saha G; Bose G; Moulik K; Zwingelstein C; Myers M; Conde-Knape K; Pietranico-Cole S; So SS
    Bioorg Med Chem Lett; 2014 Feb; 24(3):949-53. PubMed ID: 24412066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.